.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Details for Patent: 6,673,810

« Back to Dashboard

Details for Patent: 6,673,810

Title: Imidazo-heterobicycles as factor Xa inhibitors
Abstract:The present application describes imidazo-heterobicycles of formulas I and III: ##STR1## or pharmaceutically acceptable salt or prodrug forms thereof. Compounds of the present invention are useful as inhibitors of trypsin-like serine proteases, specifically factor Xa.
Inventor(s): Lam; Patrick Y. (Chadds Ford, PA), Clark; Charles G. (Cherry Hill, NJ), Han; Qi (Hockessin, DE), Richardson; Thomas E. (Albany, NY)
Assignee: Bristol-Myers Squibb Pharma Company (Princeton, NJ)
Filing Date:Jul 03, 2001
Application Number:09/898,279
Claims:1. A compound of formula III: ##STR55##

or a stereoisomer or pharmaceutically acceptable salt thereof, wherein; ring M is substituted with 0-2 R.sup.3 and is selected from the group: ##STR56## M.sub.3 is -A-B; G is a group of formula IIa or IIb: ##STR57## ring D, including the two atoms of Ring E to which it is attached, is a 5-6 membered non-aromatic ring consisting of carbon atoms, 0-1 double bonds, and from 0-2 N, and D is substituted with 0-2 R, provided that when ring D is unsubstituted, it contains at least one heteroatom; alternatively, ring D, including the two atoms of Ring E to which it is attached, is a 5-6 membered aromatic system consisting of carbon atoms and from 0-2 heteroatoms selected from the group consisting of N, O, and S, and D is substituted with 0-2 R, provided that when ring D is unsubstituted, it contains at least one heteroatom; E is selected from phenyl, pyridyl, pyrimidyl, pyrazinyl, and pyridazinyl, and is substituted with 0-1 R; R is selected from F, Cl, Br, I, OH, OCH.sub.3, OCH.sub.2 CH.sub.3, OCH(CH.sub.3).sub.2, OCH.sub.2 CH.sub.2 CH.sub.3, NH.sub.2, NH(C.sub.1-3 alkyl), N(C.sub.1-3 alkyl).sub.2, C(.dbd.NH)NH.sub.2, CH.sub.2 NH.sub.2, CH.sub.2 NH(C.sub.1-3 alkyl), CH.sub.2 N(C.sub.1-3 alkyl).sub.2, CH.sub.2 CH.sub.2 NH.sub.2, CH.sub.2 CH.sub.2 NH(C.sub.1-3 alkyl), and CH.sub.2 CH.sub.2 N(C.sub.1-3 alkyl).sub.2 ; alternatively, the bridging portion of ring D is absent, ring E is selected from phenyl, pyridyl, pyrimidyl, pyrazinyl, and pyridazinyl, and ring E is substituted with R.sup.a and R.sup.b ; R.sup.a is selected from F, Cl, Br, I, OH, OCH.sub.3, OCH.sub.2 CH.sub.3, OCH(CH.sub.3).sub.2, OCH.sub.2 CH.sub.2 CH.sub.3, CN, C(.dbd.NR.sup.8)NR.sup.7 R.sup.9, NHC(.dbd.NR.sup.8)NR.sup.7 R.sup.9, NR.sup.8 CH(.dbd.NR.sup.7), C(O)NR.sup.7 R.sup.8, (CR.sup.8 R.sup.9).sub.t NR.sup.7 R.sup.8, SH, SCH.sub.3, SCH.sub.2 CH.sub.3, SCH(CH.sub.3).sub.2, SCH.sub.2 CH.sub.2 CH.sub.3, S(O)R.sup.3b, S(O).sub.2 R.sup.3a, S(O).sub.2 NR.sup.2 R.sup.2a, and OCF.sub.3 ; R.sup.b is selected from H, F, Cl, Br, I, C.sub.1-4 alkyl, SR.sup.3, CO.sub.2 R.sup.3, NO.sub.2, (CH.sub.2).sub.t OR.sup.3, OCF.sub.3, CF.sub.3, C(O)NR.sup.7 R.sup.8, and (CR.sup.8 R.sup.9).sub.t NR.sup.7 R.sup.8 ; alternatively, R.sup.a and R.sup.b combine to form methylenedioxy or ethylenedioxy; A is selected from: C.sub.3-10 carbocycle substituted with 0-2 R.sup.4, and 5-10 membered heterocycle consisting of: carbon atoms and 1-4 heteroatoms selected from the group consisting of N, O, and S substituted with 0-2 R.sup.4 ; B is selected from: H, Y, X-Y, C(.dbd.NR.sup.2)NR.sup.2 R.sup.2a, and NR.sup.2 C(.dbd.NR.sup.2)NR.sup.2 R.sup.2a, provided that ring M and B are attached to different atoms on A; X is selected from C.sub.1-4 alkylene, --CR.sup.2 (CR.sup.2 R.sup.2b)(CH.sub.2).sub.t --, --C(O)--, --C(.dbd.NR.sup.1c)--, --CR.sup.2 (NR.sub.1c R.sup.2)--, --CR.sup.2 (OR.sup.2)--, --CR.sup.2 (SR.sup.2)--, --C(O)CR.sup.2 R.sup.2a --, --CR.sup.2 R.sup.2a C(O), --S--, --S(O)--, --S(O).sub.2 --, --SCR.sup.2 R.sup.2a --, --S(O)CR.sup.2 R.sup.2a --, --S(O).sub.2 CR.sup.2 R.sup.2a --, --CR.sup.2 R.sup.2a S--, --CR.sup.2 R.sup.2a S(O)--, --CR.sup.2 R.sup.2a S(O).sub.2 --, --S(O).sub.2 NR.sup.2 --, --NR.sup.2 S(O).sub.2 --, --NR.sup.2 S(O).sub.2 CR.sup.2 R.sup.2a --, --CR.sup.2 R.sup.2a S(O).sub.2 NR.sup.2 --, --NR.sup.2 S(O).sub.2 NR.sup.2 --, --C(O)NR.sup.2 --, --NR.sup.2 C(O)--, --C(O)NR.sup.2 CR.sup.2 R.sup.2a --, --NR.sup.2 C(O)CR.sup.2 R.sup.2a --, --CR.sup.2 R.sup.2a C(O)NR.sup.2 --, --CR.sup.2 R.sup.2a NR.sup.2 C(O)--, --NR.sup.2 C(O)O--, --OC(O)NR.sup.2 --, --NR.sup.2 C(O)NR.sup.2 --, --NR.sup.2 --, --NR.sup.2 CR.sup.2 R.sup.2a --, --CR.sup.2 R.sup.2a NR.sup.2 --, O, --CR.sup.2 R.sup.2a O--, and --OCR.sup.2 R.sup.2a --; Y is selected from: CH.sub.2 NR.sup.2 R.sup.2a ; CH.sub.2 CH.sub.2 NR.sup.2 R.sup.2a ; C.sub.3-10 carbocycle substituted with 0-2 R.sup.4a, and, 5-10 membered heterocycle consisting of: carbon atoms and 1-4 heteroatoms selected from the group consisting of N, O, and S substituted with 0-2 R.sup.4a ; Z.sup.2 is selected from H, C.sub.1-4 alkyl, phenyl, benzyl, C(O)R.sup.3, and S(O).sub.p R.sup.3c ; R.sup.1a is selected from H, --(CH.sub.2).sub.r R.sup.1b, --CH.dbd.CH--R.sup.1b, NCH.sub.2 R.sup.1c, OCH.sub.2 R.sup.1c, SCH.sub.2 R.sup.1c, NH(CH.sub.2).sub.2 (CH.sub.2).sub.t R.sup.1b, O(CH.sub.2).sub.2 (CH.sub.2).sub.t R.sup.1b, S(CH.sub.2).sub.2 (cH.sub.2).sub.t R.sup.1b S(O).sub.p (CH.sub.2).sub.r R.sup.1d, O(CH.sub.2).sub.r R.sup.1d, NR.sup.3 (CH.sub.2).sub.r R.sup.1d, OC(O)NR.sup.3 (CH.sub.2).sub.r R.sup.1d, NR.sup.3 C(O)NR.sup.3 (CH.sub.2).sub.r R.sup.1d, NR.sup.3 C(O)O(CH.sub.2).sub.r R.sup.1d, and NR.sup.3 C(O)(CH.sub.2).sub.r R.sup.1d, provided that R.sup.1a forms other than an N-halo, N--N, N--S, N--O, or N--CN bond; R.sup.1b is selected from H, C.sub.1-3 alkyl, F, Cl, Br, I, --CN, --CHO, (CF.sub.2).sub.r CF.sub.3, (CH.sub.2).sub.r OR.sup.2, NR.sup.2 R.sup.2a, C(O)R.sup.2c, OC(O)R.sup.2, (CF.sub.2).sub.r CO.sub.2 R.sup.2a, S(O).sub.p R.sup.2b, NR.sup.2 (CH.sub.2).sub.r OR.sup.2, C(.dbd.NR.sup.2c)NR.sup.2 R.sup.2a, NR.sup.2 C(O)R.sup.2b, NR.sup.2 C(O)NHR.sup.2b, NR.sup.2 C(O).sub.2 R.sup.2a, OC(O)NR.sup.2a R.sup.2b, C(O)NR.sup.2 R.sup.2a, C(O)NR.sup.2 (CH.sub.2).sub.r OR.sup.2, SO.sub.2 NR.sup.2 R.sup.2a, NR.sup.2 SO.sub.2 R.sup.2b, C.sub.3-6 carbocycle substituted with 0-2 R.sup.4a, and 5-10 membered heterocycle consisting of carbon atoms and from 1-4 heteroatoms selected from the group consisting of N, O, and S substituted with 0-2 R.sup.4a, provided that R.sup.1b forms other than an N-halo, N--N, N--S, N--O, or N--CN bond; R.sup.1c is selected from H, CH(CH.sub.2 OR.sup.2).sub.2, C(O)R.sup.2c, C(O)NR.sup.2 R.sup.2a, S(O)R.sup.2b, S(O).sub.2 R.sup.2b, and SO.sub.2 NR.sup.2 R.sup.2a ; R.sup.1d is selected from C.sub.3-6 carbocycle substituted with 0-2 R.sup.4a, and 5-10 membered heterocycle consisting of carbon atoms and from 1-4 heteroatoms selected from the group consisting of N, O, and S substituted with 0-2 R.sup.4a, provided that R.sup.1d forms other than an N--N, N--S, or N--O bond; R.sup.2, at each occurrence, is selected from H, CF.sub.3, C.sub.1-6 alkyl, benzyl, C.sub.3-6 carbocycle substituted with 0-2 R.sup.4b, a C.sub.3-6 carbocyclic-CH.sub.2 -residue substituted with 0-2 R.sup.4b, and 5-6 membered heterocycle consisting of: carbon atoms and 1-4 heteroatoms selected from the group consisting of N, O, and S substituted with 0-2 R.sup.4b ; R.sup.2a, at each occurrence, is selected from H, CF.sub.3, C.sub.1-6 alkyl, benzyl, C.sub.3-6 carbocycle substituted with 0-2 R.sup.4b, and 5-6 membered heterocycle consisting of: carbon atoms and 1-4 heteroatoms selected from the group consisting of N, O, and S substituted with 0-2 R.sup.4b ; R.sup.2b, at each occurrence, is selected from CF.sub.3, C.sub.1-4 alkoxy, C.sub.1-6 alkyl, benzyl, C.sub.3-6 carbocycle substituted with 0-2 R.sup.4b, and 5-6 membered heterocycle consisting of: carbon atoms and 1-4 heteroatoms selected from the group consisting of N, O, and S substituted with 0-2 R.sup.4b ; R.sup.2c, at each occurrence, is selected from CF.sub.3, OH, C.sub.1-4 alkoxy, C.sub.1-6 alkyl, benzyl, C.sub.3-6 carbocyclic residue substituted with 0-2 R.sup.4b, and 5-6 membered heterocyclic system containing from 1-4 heteroatoms selected from the group consisting of N, O, and S substituted with 0-2 R.sup.4b ; alternatively, R.sup.2 and R.sup.2a, together with the atom to which they are attached, combine to form a 5 or 6 membered saturated, partially saturated or unsaturated ring substituted with 0-2 R.sup.4b and consisting of: 0-1 additional heteroatoms selected from the group consisting of N, O, and 5; R.sup.3, at each occurrence, is selected from H, C.sub.1-4 alkyl, and phenyl; R.sup.3a, at each occurrence, is selected from H, C.sub.1-4 alkyl, benzyl, and phenyl; R.sup.3b, at each occurrence, is selected from H, C.sub.1-4 alkyl, and phenyl; R.sup.3c, at each occurrence, is selected from C.sub.1-4 alkyl, benzyl, and phenyl; R.sup.3d, at each occurrence, is selected from H, C.sub.1-4 alkyl, C.sub.1-4 alkyl-phenyl, and C(.dbd.O)R.sup.3c ; R.sup.4, at each occurrence, is selected from H, .dbd.O, (CH.sub.2).sub.r OR.sup.2, F, Cl, Br, I, C.sub.1-4 alkyl, --CN, NO.sub.2, (CH.sub.2).sub.r NR.sup.2 R.sup.2a, (CH.sub.2).sub.r C(O)R.sup.2c, NR.sup.2 C(O)R.sup.2b, C(O)NR.sup.2 R.sup.2a, NR.sup.2 C(O)NR.sup.2 R.sup.2a, C(.dbd.NR.sup.2)NR.sup.2 R.sup.2a, C(.dbd.NS(O).sub.2 R.sup.5)NR.sup.2 R.sup.2a, NHC(.dbd.NR.sup.2)NR.sup.2 R.sup.2a, C(O)NHC(.dbd.NR.sup.2)NR.sup.2 R.sup.2a, SO.sub.2 NR.sup.2 R.sup.2a, NR.sup.2 SO.sub.2 NR.sup.2 R.sup.2a, NR.sup.2 SO.sub.2 --C.sub.1-4 alkyl, NR.sup.2 SO.sub.2 R.sup.5, S(O).sub.p R.sup.5, (CF.sub.2).sub.r CF.sub.3, NCH.sub.2 R.sup.1c, OCH.sub.2 R.sup.1c, SCH.sub.2 R.sup.1c, N(CH.sub.2).sub.2 (CH.sub.2).sub.t R.sup.1b, O(CH.sub.2).sub.2 (CH.sub.2).sub.t R.sup.1b, and S(CH.sub.2).sub.2 (CH.sub.2).sub.t R.sup.1b ; alternatively, one R.sup.4 is a 5-6 membered aromatic heterocycle consisting of: carbon atoms and 1-4 heteroatoms selected from the group consisting of N, O, and S; R.sup.4a, at each occurrence, is selected from H, .dbd.O, (CH.sub.2).sub.r OR.sup.2, (CH.sub.2).sub.r --F, (CH.sub.2).sub.r --Br, (CH.sub.2).sub.r --Cl, Cl, Br, F, I, C.sub.1-4 alkyl, s--CN, NO.sub.2, (CH.sub.2).sub.r NR.sup.2 R.sup.2a, (CH.sub.2).sub.r C(O)R.sup.2c, NR.sup.2 C(O)R.sup.2b, C(O)NR.sup.2 R.sup.2a, (CH.sub.2).sub.r N.dbd.CHOR.sup.3, C(O)NH(CH.sub.2).sub.2 NR.sup.2 R.sup.2a, NR.sup.2 C(O)NR.sup.2 R.sup.2a, C(.dbd.NR.sup.2)NR.sup.2 R.sup.2a, NHC(.dbd.NR.sup.2)NR.sup.2 R.sup.2a, SO.sub.2 NR.sup.2 R.sup.2a, NR.sup.2 SO.sub.2 NR.sup.2 R.sup.2a, NR.sup.2 SO.sub.2 --C.sub.1-4 alkyl, C(O)NHSO.sub.2 --C.sub.1-4 alkyl, NR.sup.2 SO.sub.2 R.sup.5, S(O).sub.p R.sup.5, and (CF.sub.2).sub.r CF.sub.3 ; alternatively, one R.sup.4a is phenyl substituted with 0-1 R.sup.5 or a 5-6 membered aromatic heterocycle consisting of: carbon atoms and 1-4 heteroatoms selected from the group consisting of N, O, and S substituted with 0-1 R.sup.5 ; R.sup.4b, at each occurrence, is selected from H, .dbd.O, (CH.sub.2).sub.r OR.sup.3, F, Cl, Br, I, C.sub.1-4 alkyl, --CN, NO.sub.2, (CH.sub.2).sub.r NR.sup.3 R.sup.3a, (CH.sub.2).sub.r C(O)R.sup.3, (CH.sub.2).sub.r C(O)OR.sup.3c, NR.sup.3 C(O)R.sup.3a, C(O)NR.sup.3 R.sup.3a, NR.sup.3 C(O)NR.sup.3 R.sup.3a, C(.dbd.NR.sup.3)NR.sup.3 R.sup.3a, NR.sup.3 C(.dbd.NR.sup.3)NR.sup.3 R.sup.3a, SO.sub.2 NR.sup.3 R.sup.3a, NR.sup.3 SO.sub.2 NR.sup.3 R.sup.3a, NR.sup.3 SO.sub.2 --C.sub.1-4 alkyl, NR.sup.3 SO.sub.2 CF.sub.3, NR.sup.3 SO.sub.2 -phenyl, S(O).sub.p CF.sub.3, S(O).sub.p --C.sub.1-4 alkyl, S(O).sub.p -phenyl, and (CF.sub.2).sub.r CF.sub.3 ; R.sup.5, at each occurrence, is selected from H, C.sub.1-6 alkyl, .dbd.O, (CH.sub.2).sub.r OR.sup.3, F, Cl, Br, I, C.sub.1-4 alkyl, --CN, NO.sub.2, (CH.sub.2).sub.r NR.sup.3 R.sup.3a, (CH.sub.2).sub.r C(O)R.sup.3, (CH.sub.2).sub.r C(O)OR.sup.3c, NR.sup.3 C(O)R.sup.3a, C(O)NR.sup.3 R.sup.3a, NR.sup.3 C(O)NR.sup.3 R.sup.3a, CH(.dbd.NOR.sup.3d), C(.dbd.NR.sup.3)NR.sup.3 R.sup.3a, NR.sup.3 C(.dbd.NR.sup.3)NR.sup.3 R.sup.3a, SO.sub.2 NR.sup.3 R.sup.3a, NR.sup.3 SO.sub.2 NR.sup.3 R.sup.3a, NR.sup.3 SO.sub.2 --C.sub.1-4 alkyl, NR.sup.3 SO.sub.2 CF.sub.3, NR.sup.3 SO.sub.2 -phenyl, S(O).sub.p CF.sub.3, S(O).sub.p C.sub.1-4 alkyl, S(O).sub.p -phenyl, (CF.sub.2).sub.r CF.sub.3, phenyl substituted with 0-2 R.sup.6, naphthyl substituted with 0-2 R.sup.6, and benzyl substituted with 0-2 R.sup.6 ; R.sup.6, at each occurrence, is selected from H, OH, (CH.sub.2).sub.r OR.sup.2, halo, C.sub.1-4 alkyl, CN, NO.sub.2, (CH.sub.2).sub.r NR.sup.2 R.sup.2a,(CH.sub.2).sub.r C(O)R.sup.2b, NR.sup.2 C(O)R.sup.2b, NR.sup.2 C(O)NR.sup.2 R.sup.2a, C(.dbd.NH)NH.sub.2, NHC(.dbd.NH)NH.sub.2, SO.sub.2 NR.sup.2 R.sup.2a, NR.sup.2 SO.sub.2 NR.sup.2 R.sup.2a, and NR.sup.2 SO.sub.2 C.sub.1-4 alkyl; R.sup.7, at each occurrence, is selected from H, OH, C.sub.1-6 alkyl, C.sub.1-6 alkylcarbonyl, C.sub.1-6 alkoxy, C.sub.1-4 alkoxycarbonyl, (CH.sub.2).sub.n -phenyl, C.sub.6 aryloxy, C.sub.6 aryloxycarbonyl, C.sub.6-10 arylmethylcarbonyl, C.sub.1-4 alkylcarbonyloxy C.sub.1-4 alkoxycarbonyl, C.sub.6-10 arylcarbonyloxy C.sub.1-4 alkoxycarbonyl, C.sub.1-6 alkylaminocarbonyl, phenylaminocarbonyl, and phenyl C.sub.1-4 alkoxycarbonyl; R.sup.8, at each occurrence, is selected from H, C.sub.1-6 alkyl, and (CH.sub.2).sub.n -phenyl; alternatively, R.sup.7 and R.sup.8 combine to form a 5 or 6 membered saturated, ring which contains from 0-1 additional heteroatoms selected from the group consisting of N, O, and S; R.sup.9, at each occurrence, is selected from H, C.sub.1-6 alkyl, and (CH.sub.2).sub.n -phenyl; n, at each occurrence, is selected from 0,1, 2, and 3; p, at each occurrence, is selected from 0, 1, and 2; r, at each occurrence, is selected from 0, 1, 2, 3, 4, 5, and 6; s, at each occurrence, is selected from 0, 1, and 2; and, t, at each occurrence, is selected from 0, 1, 2, and 3.

2. A compound according to claim 1, wherein: Z.sup.2 is selected from H, C.sub.1-4 alkyl, phenyl, benzyl, C(O)R.sup.3, and S(O).sub.p R.sup.3c ; G is selected from the group: ##STR58## ##STR59## ##STR60## ##STR61## ##STR62## A is selected from one of the following carbocyclic and heterocyclic systems which are substituted with 0-2 R.sup.4 ; phenyl, piperidinyl, piperazinyl, pyridyl, pyrimidyl, furanyl, morpholinyl, thiophenyl, pyrrolyl, pyrrolidinyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, pyrazolyl, imidazolyl, oxadiazolyl, thiadiazolyl, triazolyl, 1,2,3-oxadiazolyl, 1,2,4-oxadiazolyl, 1,2,5-oxadiazolyl, 1,3,4-oxadiazolyl, 1,2,3-thiadiazolyl, 1,2,4-thiadiazolyl, 1,2,5-thiadiazolyl, 1,3,4-thiadiazolyl, 1,2,3-triazolyl, 1,2,4-triazolyl, 1,2,5-triazolyl, 1,3,4-triazolyl, benzofuranyl, benzothiofuranyl, indolyl, benzimidazolyl, benzoxazolyl, benzthiazolyl, indazolyl, benzisoxazolyl, benzisothiazolyl, and isoindazolyl; B is Y or X-Y; X is selected from C.sub.1-4 alkylene, --C(O)--, --C(.dbd.NR)--, --CR.sup.2 (NR.sup.2 R.sup.2a)--, --C(O)CR.sup.2 R.sup.2a --, --CR.sup.2 R.sup.2a C(O), --C(O)NR.sup.2 --, --NR.sup.2 C(O)--, --C(O)NR.sup.2 CR.sup.2 R.sup.2a --, --NR.sup.2 C(O)CR.sup.2 R.sup.2a --, --CR.sup.2 R.sup.2a C(O)NR.sup.2 --, --CR.sup.2 R.sup.2a NR.sup.2 C(O)--, --NR.sup.2 C(O)NR.sup.2 --, --NR.sup.2 --, --NR.sup.2 CR.sup.2 R.sup.2a --, --CR.sup.2 R.sup.2a NR.sup.2 --, O, --CR.sup.2 R.sup.2a O--, and --OCR.sup.2 R.sup.2a --; Y is CH.sub.2 NR.sup.2 R.sup.2a or CH.sub.2 CH.sub.2 NR.sup.2 R.sup.2a ; alternatively, Y is selected from one of the following carbocyclic and heterocyclic systems that are substituted with 0-2 R.sup.4a ; cyclopropyl, cyclopentyl, cyclohexyl, phenyl, piperidinyl, piperazinyl, pyridyl, pyrimidyl, furanyl, morpholinyl, thiophenyl, pyrrolyl, pyrrolidinyl, oxazolyl, isoxazolyl, isoxazolinyl, thiazolyl, isothiazolyl, pyrazolyl, imidazolyl, oxadiazolyl, thiadiazolyl, triazolyl, 1,2,3-oxadiazolyl, 1,2,4-oxadiazolyl, 1,2,5-oxadiazolyl, 1,3,4-oxadiazolyl, 1,2,3-thiadiazolyl, 1,2,4-thiadiazolyl, 1,2,5-thiadiazolyl, 1,3,4-thiadiazolyl, 1,2,3-triazolyl, 1,2,4-triazolyl, 1,2,5-triazolyl, 1,3,4-triazolyl, benzofuranyl, benzothiofuranyl, indolyl, benzimidazolyl, benzoxazolyl, benzthiazolyl, indazolyl, benzisoxazolyl, benzisothiazolyl, and isoindazolyl; alternatively, Y is selected from the following bicyclic heteroaryl ring systems: ##STR63## K is selected from O, S, NH, and N.

3. A compound according to claim 2, wherein: G is selected from the group: ##STR64## ##STR65## s is 0.

4. A compound according to claim 3, wherein: G is selected from: ##STR66##

5. A compound according to claim 4, wherein: A is selected from phenyl, pyridyl, and pyrimidyl, and is substituted with 0-2 R.sup.4 ; and, B is selected from phenyl, pyrrolidino, N-pyrrolidino-carbonyl, morpholino, N-morpholino-carbonyl, 1,2,3-triazolyl, imidazolyl, and benzimidazolyl, and is substituted with 0-1 R.sup.4a ; R.sup.2, at each occurrence, is selected from H, CH.sub.3, CH.sub.2 CH.sub.3, cyclopropylmethyl, cyclobutyl, and cyclopentyl; R.sup.2a at each occurrence, is H or CH.sub.3 ; alternatively, R.sup.2 and R.sup.2a, together with the atom to which they are attached, combine to form pyrrolidine substituted with 0-2 R.sup.4b ; R.sup.4, at each occurrence, is selected from OH, (CH.sub.2).sub.r OR.sup.2, halo, C.sub.1-4 alkyl, (CH.sub.2).sub.r NR.sup.2 R.sup.2a, and (CF.sub.2).sub.r CF.sub.3 ; R.sup.4a is selected from C.sub.1-4 alkyl, CF.sub.3, (CH.sub.2).sub.r OR.sup.2, (CH.sub.2).sub.r NR.sup.2 R.sup.2a, S(O).sub.p R.sup.5, SO.sub.2 NR.sup.2 R.sup.2a, and 1-CF.sub.3 -tetrazol-2-yl; R.sup.4b, at each occurrence, is selected from H, CH.sub.3, and OH; R.sup.5, at each occurrence, is selected from CF.sub.3, C.sub.1-6 alkyl, phenyl, and benzyl; and, r, at each occurrence, is selected from 0, 1, and 2.

6. A compound according to claim 5, wherein: A is selected from the group: phenyl, 2-pyridyl, 3-pyridyl, 2-pyrimidyl, 2--Cl-phenyl, 3--Cl-phenyl, 2-F-phenyl, 3-F-phenyl, 2-methylphenyl, 2-aminophenyl, and 2-methoxyphenyl; and, B is selected from the group: 2-(aminosulfonyl)phenyl, 2-(methylaminosulfonyl)phenyl, 1-pyrrolidinocarbonyl, 2-(methylsulfonyl)phenyl, 2-(N,N-dimethylaminomethyl)phenyl, 2-(N-pyrrolidinylmethyl)phenyl, 1-methyl-2-imidazolyl, 2-methyl-1-imidazolyl, 2-(dimethylaminomethyl)-1-imidazolyl, 2-(N-(cyclopropylmethyl)aminomethyl)phenyl, 2-(N-(cyclobutyl)aminomethyl)phenyl, 2-(N-(cyclopentyl)aminomethyl)phenyl, and 2-(N-(3-hydroxypyrrolidinyl)methyl)phenyl.

7. A compound according to claim 1, wherein the compound is selected from: 1-(4-methoxyphenyl)-6-{2'-[aminomethyl]-1,1'-biphenyl-4-yl}-7-oxo-4,5,6,7-t etrahydro-1H-imidazolo[4,5-c]pyridine; 1-(4-methoxyphenyl)-6-{2'-[(methylamino)methyl]-1,1'-biphenyl-4-yl}-7-oxo-4 ,5,6,7-tetrahydro-1H-imidazolo[4,5-c]pyridine; 1-(4-methoxyphenyl)-6-{2'-[(dimethylamino)methyl]-1,1'-biphenyl-4-yl}-7-oxo -4,5,6,7-tetrahydro-1H-imidazolo[4,5-c]pyridine; 1-(4-methoxyphenyl)-6-{2'-[(N-ethyl-N-methylamino)methyl]-1,1'-biphenyl-4-y l}-7-oxo-4,5,6,7-tetrahydro-1H-imidazolo[4,5-c]pyridine; 1-(4-methoxyphenyl)-6-{2'-[(N-methyl-N-propylamino)methyl]-1,1'-biphenyl-4- yl}-7-oxo-4,5,6,7-tetrahydro-1H-imidazolo[4,5-c]pyridine; 1-(4-methoxyphenyl)-6-{2-[(N-t-butylamino)methyl]-1,1'-biphenyl-4-yl}-7-oxo -4,5,6,7-tetrahydro-1H-imidazolo[4,5-c]pyridine; 6-(2'-{[1-pyrrolidinyl]methyl}-1,1'-biphenyl-4-yl)-1-(4-methoxyphenyl)-7-ox o-4,5,6,7-tetrahydro-1H-imidazolo[4,5-c]pyridine; 6-(2'-{[(3S)-3-hydroxy-1-pyrrolidinyl]methyl}-1,1'-biphenyl-4-yl)-1-(4-meth oxyphenyl)-7-oxo-4,5,6,7-tetrahydro-1H-imidazolo[4,5-c]pyridine; 6-(2'-{[(3R)-3-hydroxy-1-pyrrolidinyl]methyl}-1,1'-biphenyl-4-yl)-1-(4-meth oxyphenyl)-7-oxo-4,5,6,7-tetrahydro-1H-imidazolo[4,5-c]pyridine; 6-{2'-[(4-hydroxy-1-piperidinyl)methyl]-1,1'-biphenyl-4-yl}-1-(4-methoxyphe nyl)-7-oxo-4,5,6,7-tetrahydro-1H-imidazolo[4,5-c]pyridine; 6-{4-[3-(aminosulfonyl)-4-pyridinyl]phenyl}-1-(4-methoxyphenyl)-7-oxo-4,5,6 ,7-tetrahydro-1H-imidazolo[4,5-c]pyridine; 6-(4-{2-[(dimethylamino)methyl]-1H-imidazol-1-yl}phenyl)-1-(4-methoxyphenyl )-7-oxo-4,5,6,7-tetrahydro-1H-imidazolo[4,5-c]pyridine; 1-(4-methoxyphenyl)-6-[4-(2-methyl-1H-imidazol-1-yl)phenyl]-7-oxo-4,5,6,7-t etrahydro-1H-imidazolo[4,5-c]pyridine; 6-(2'-{[(2-hydroxyethyl)(methyl)amino]methyl}-1,1'-biphenyl-4-yl)-1-(4-meth oxyphenyl)-7-oxo-4,5,6,7-tetrahydro-1H-imidazolo[4,5-c]pyridine; 6-(2'-{[(2-hydroxyethyl)amino]methyl}-1,1'-biphenyl-4-yl)-1-(4-methoxypheny l)-7-oxo-4,5,6,7-tetrahydro-1H-imidazolo[4,5-c]pyridine; 1-(4-methoxyphenyl)-6-(4-{2-[(methylamino)methyl]-1H-imidazol-1-yl}phenyl)- 7-oxo-4,5,6,7-tetrahydro-1H-imidazolo[4,5-c]pyridine; 6-(2'-aminosulfonyl-1,1'-biphenyl-4-yl)-1-(4-methoxyphenyl)-7-oxo-4,5,6,7-t etrahydro-1H-imidazolo[4,5-c]pyridine; 6-(2'-methylsulfonyl-1,1'-biphenyl-4-yl)-1-(4-methoxyphenyl)-7-oxo-4,5,6,7- tetrahydro-1H-imidazolo[4,5-c]pyridine; 1-(4-methoxyphenyl)-6-{2'-[aminomethyl]-3-fluoro-1,1'-biphenyl-4-yl}-7-oxo- 4,5,6,7-tetrahydro-1H-imidazolo[4,5-c]pyridine; 1-(4-methoxyphenyl)-6-{2'-[(methylamino)methyl]-3-fluoro-1,1'-biphenyl-4-yl }-7-oxo-4,5,6,7-tetrahydro-1H-imidazolo[4,5-c]pyridine; 1-(4-methoxyphenyl)-6-{2'-[(dimethylamino)methyl]-3-fluoro-1,1'-biphenyl-4- yl}-7-oxo-4,5,6,7-tetrahydro-1H-imidazolo[4,5-c]pyridine; 1-(4-methoxyphenyl)-6-{2'-[(N-ethyl-N-methylamino)methyl]-3-fluoro-1,1'-bip henyl-4-yl}-7-oxo-4,5,6,7-tetrahydro-1H-imidazolo[4,5-c]pyridine; 1-(4-methoxyphenyl)-6-{2'-[(N-methyl-N-propylamino)methyl]-3-fluoro-1,1'-bi phenyl-4-yl}-7-oxo-4,5,6,7-tetrahydro-1H-imidazolo[4,5-c]pyridine; 1-(4-methoxyphenyl)-6-{2'-[(N-t-butylamino)methyl]-3-fluoro-1,1'-biphenyl-4 -yl}-7-oxo-4,5,6,7-tetrahydro-1H-imidazolo[4,5-c]pyridine; 6-(2'-([1-pyrrolidinyl]methyl}-3-fluoro-1,1'-biphenyl-4-yl)-1-(4-methoxyphe nyl)-7-oxo-4,5,6,7-tetrahydro-1H-imidazolo[4,5-c]pyridine; 6-(2'-{[(3S)-3-hydroxy-1-pyrrolidinyl]methyl}-3-fluoro-1,1'-biphenyl-4-yl)- 1-(4-methoxyphenyl)-7-oxo-4,5,6,7-tetrahydro-1H-imidazolo[4,5-c]pyridine; 6-(2'-{[(3R)-3-hydroxy-1-pyrrolidinyl]methyl}-3-fluoro-1,1'-biphenyl-4-yl)- 1-(4-methoxyphenyl)-7-oxo-4,5,6,7-tetrahydro-1H-imidazolo[4,5-c]pyridine; 6-{2'-[(4-hydroxy-1-piperidinyl)methyl]-3-fluoro-1,1'-biphenyl-4-yl}-1-(4-m ethoxyphenyl)-7-oxo-4,5,6,7-tetrahydro-1H-imidazolo[4,5-c]pyridine; 6-{4-[3-(aminosulfonyl)-4-pyridinyl]-2-fluoro-phenyl}-1-(4-methoxyphenyl)-7 -oxo-4,5,6,7-tetrahydro-1H-imidazolo[4,5-c]pyridine; 6-(4-{2-[(dimethylamino)methyl]-1H-imidazol-1-yl}-2-fluoro-phenyl)-1-(4-met hoxyphenyl)-7-oxo-4,5,6,7-tetrahydro-1H-imidazolo[4,5-c]pyridine; 1-(4-methoxyphenyl)-6-[4-(2-methyl-1H-imidazol-1-yl)-2-fluoro-phenyl]-7-oxo -4,5,6,7-tetrahydro-1H-imidazolo[4,5-c]pyridine; 6-(2'-{[(2-hydroxyethyl)(methyl)amino]methyl}-3-fluoro-1,1'-biphenyl-4-yl)- 1-(4-methoxyphenyl)-7-oxo-4,5,6,7-tetrahydro-1H-imidazolo[4,5-c]pyridine; 6-(2'-{[(2-hydroxyethyl)amino]methyl}-3-fluoro-1,1'-biphenyl-4-yl)-1-(4-met hoxyphenyl)-7-oxo-4,5,6,7-tetrahydro-1H-imidazolo[4,5-c]pyridine; 1-(4-methoxyphenyl)-6-(4-{2-[(methylamino)methyl]-1H-imidazol-1-yl}-2-fluor o-phenyl)-7-oxo-4,5,6,7-tetrahydro-1H-imidazolo[4,5-c]pyridine; 6-(2'-aminosulfonyl-3-fluoro-1,1'-biphenyl-4-yl)-1-(4-methoxyphenyl)-7-oxo- 4,5,6,7-tetrahydro-1H-imidazolo[4,5-c]pyridine; 6-(2'-methylsulfonyl-3-fluoro-1,1'-biphenyl-4-yl)-1-(4-methoxyphenyl)-7-oxo -4,5,6,7-tetrahydro-1H-imidazolo[4,5-c]pyridine; 1-(3-aminomethylphenyl)-6-{2'-[aminomethyl]-1,1'-biphenyl-4-yl}-7-oxo-4,5,6 ,7-tetrahydro-1H-imidazolo[4,5-c]pyridine; 1-(3-aminomethylphenyl)-6-{2'-[(methylamino)methyl]-1,1'-biphenyl-4-yl}-7-o xo-4,5,6,7-tetrahydro-1H-imidazolo[4,5-c]pyridine; 1-(3-aminomethylphenyl)-6-{2'-[(dimethylamino)methyl]-1,1'-biphenyl-4-yl}-7 -oxo-4,5,6,7-tetrahydro-1H-imidazolo[4,5-c]pyridine; 1-(3-aminomethylphenyl)-6-{2'-[(N-ethyl-N-methylamino)methyl]-1,1'-biphenyl -4-yl}-7-oxo-4,5,6,7-tetrahydro-1H-imidazolo[4,5-c]pyridine; 1-(3-aminomethylphenyl)-6-{2'-[(N-methyl-N-propylamino)methyl]-1,1'-bipheny l-4-yl}-7-oxo-4,5,6,7-tetrahydro-1H-imidazolo[4,5-c]pyridine; 1-(3-aminomethylphenyl)-6-{2'-[(N-t-butylamino)methyl]-1,1'-biphenyl-4-yl}- 7-oxo-4,5,6,7-tetrahydro-1H-imidazolo[4,5-c]pyridine; 6-(2'-{[1-pyrrolidinyl]methyl}-1,1'-biphenyl-4-yl)-1-(3-aminomethylphenyl)- 7-oxo-4,5,6,7-tetrahydro-1H-imidazolo[4,5-c]pyridine; 6-(2'-{[(3S)-3-hydroxy-1-pyrrolidinyl]methyl}-1,1'-biphenyl-4-yl)-1-(3-amin omethylphenyl)-7-oxo-4,5,6,7-tetrahydro-1H-imidazolo[4,5-c]pyridine; 6-(2'-{[(3R)-3-hydroxy-1-pyrrolidinyl]methyl}-1,1'-biphenyl-4-yl)-1-(3-amin omethylphenyl)-7-oxo-4,5,6,7-tetrahydro-1H-imidazolo[4,5-c]pyridine; 6-{2'-[(4-hydroxy-1-piperidinyl)methyl]-1,1'-biphenyl-4-yl}-1-(3-aminomethy lphenyl)-7-oxo-4,5,6,7-tetrahydro-1H-imidazolo[4,5-c]pyridine; 6-{4-[3-(aminosulfonyl)-4-pyridinyl]phenyl}-1-(3-aminomethylphenyl)-7-oxo-4 ,5,6,7-tetrahydro-1H-imidazolo[4,5-c]pyridine; 6-(4-(2-[(dimethylamino)methyl]-1H-imidazol-1-yl}phenyl)-1-(3-aminomethylph enyl)-7-oxo-4,5,6,7-tetrahydro-1H-imidazolo[4,5-c]pyridine; 1-(3-aminomethylphenyl)-6-[4-(2-methyl-1H-imidazol-1-yl)phenyl]-7-oxo-4,5,6 ,7-tetrahydro-1H-imidazolo[4,5-c]pyridine; 6-(2'-{[(2-hydroxyethyl)(methyl)amino]methyl}-1,1'-biphenyl-4-yl)-1-(3-amin omethylphenyl)-7-oxo-4,5,6,7-tetrahydro-1H-imidazolo[4,5-c]pyridine; 6-(2'-{[(2-hydroxyethyl)amino]methyl}-1,1'-biphenyl-4-yl)-1-(3-aminomethylp henyl)-7-oxo-4,5,6,7-tetrahydro-1H-imidazolo[4,5-c]pyridine; 1-(3-aminomethylphenyl)-6-(4-{2-[(methylamino)methyl]-1H-imidazol-1-yl}phen yl)-7-oxo-4,5,6,7-tetrahydro-1H-imidazolo[4,5-c]pyridine; 6-(2'-aminosulfonyl-1,1'-biphenyl-4-yl)-1-(3-aminomethylphenyl)-7-oxo-4,5,6 ,7-tetrahydro-1H-imidazolo[4,5-c]pyridine; 6-(2'-methylsulfonyl-1,1'-biphenyl-4-yl)-1-(3-aminomethylphenyl)-7-oxo-4,5, 6,7-tetrahydro-1H-imidazolo[4,5-c]pyridine; 1-(3-aminomethylphenyl)-6-{2'-[aminomethyl]-3-fluoro-1,1'-biphenyl-4-yl}-7- oxo-4,5,6,7-tetrahydro-1H-imidazolo[4,5-c]pyridine; 1-(3-aminomethylphenyl)-6-{2'-[(methylamino)methyl]-3-fluoro-1,1'-biphenyl- 4-yl}-7-oxo-4,5,6,7-tetrahydro-1H-imidazolo[4,5-c]pyridine; 1-(3-aminomethylphenyl)-6-{2'-[(dimethylamino)methyl]-3-fluoro-1,1'-bipheny l-4-yl}-7-oxo-4,5,6,7-tetrahydro-1H-imidazolo[4,5-c]pyridine; 1-(3-aminomethylphenyl)-6-{2'-[(N-ethyl-N-methylamino)methyl]-3-fluoro-1,1' -biphenyl-4-yl}-7-oxo-4,5,6,7-tetrahydro-1H-imidazolo[4,5-c]pyridine; 1-(3-aminomethylphenyl)-6-{2'-[(N-methyl-N-propylamino)methyl]-3-fluoro-1,1 '-biphenyl-4-yl}-7-oxo-4,5,6,7-tetrahydro-1H-imidazolo[4,5-c]pyridine; 1-(3-aminomethylphenyl)-6-{2'-[(N-t-butylamino)methyl]-3-fluoro-1,1'-biphen yl-4-yl}-7-oxo-4,5,6,7-tetrahydro-1H-imidazolo[4,5-c]pyridine; 6-(2'-{[1-pyrrolidinyl]methyl}-3-fluoro-1,1'-biphenyl-4-yl)-1-(3-aminomethy lphenyl)-7-oxo-4,5,6,7-tetrahydro-1H-imidazolo[4,5-c]pyridine; 6-(2'-([(3S)-3-hydroxy-1-pyrrolidinyl]methyl}-3-fluoro-1,1'-biphenyl-4-yl)- 1-(3-aminomethylphenyl)-7-oxo-4,5,6,7-tetrahydro-1H-imidazolo[4,5-c]pyridin e; 6-(2'-{[(3R)-3-hydroxy-1-pyrrolidinyl]methyl}-3-fluoro-1,1'-biphenyl-4-yl)- 1-(3-aminomethylphenyl)-7-oxo-4,5,6,7-tetrahydro-1H-imidazolo[4,5-c]pyridin e; 6-{2'-[(4-hydroxy-1-piperidinyl)methyl]-3-fluoro-1,1'-biphenyl-4-yl}-1-(3-a minomethylphenyl)-7-oxo-4,5,6,7-tetrahydro-1H-imidazolo[4,5-c]pyridine; 6-{4-[3-(aminosulfonyl)-4-pyridinyl]-2-fluoro-phenyl}-1-(3-aminomethylpheny l)-7-oxo-4,5,6,7-tetrahydro-1H-imidazolo[4,5-c]pyridine; 6-(4-{2-[(dimethylamino)methyl]-1H-imidazol-1-yl}-2-fluoro-phenyl)-1-(3-ami nomethylphenyl)-7-oxo-4,5,6,7-tetrahydro-1H-imidazolo[4,5-c]pyridine; 1-(3-aminomethylphenyl)-6-[4-(2-methyl-1H-imidazol-1-yl)-2-fluoro-phenyl]-7 -oxo-4,5,6,7-tetrahydro-1H-imidazolo[4,5-c]pyridine; 6-(2'-{[(2-hydroxyethyl)(methyl)amino]methyl}-3-fluoro-1,1'-biphenyl-4-yl)- 1-(3-aminomethylphenyl)-7-oxo-4,5,6,7-tetrahydro-1H-imidazolo[4,5-c]pyridin e; 6-(2'-{[(2-hydroxyethyl)amino]methyl}-3-fluoro-1,1'-biphenyl-4-yl)-1-(3-ami nomethylphenyl)-7-oxo-4,5,6,7-tetrahydro-1H-imidazolo[4,5-c]pyridine; 1-(3-aminomethylphenyl)-6-(4-{2-[(methylamino)methyl]-1H-imidazol-1-yl}-2-f luoro-phenyl)-7-oxo-4,5,6,7-tetrahydro-1H-imidazolo[4,5-c]pyridine; 6-(2'-aminosulfonyl-3-fluoro-1,1'-biphenyl-4-yl)-1-(3-aminomethylphenyl)-7- oxo-4,5,6,7-tetrahydro-1H-imidazolo[4,5-c]pyridine; 6-(2'-methylsulfonyl-3-fluoro-1,1'-biphenyl-4-yl)-1-(3-aminomethylphenyl)-7 -oxo-4,5,6,7-tetrahydro-1H-imidazolo[4,5-c]pyridine; 1-(3-aminobenzisoxazol-5'-yl)-6-{2'-[aminomethyl]-1,1'-biphenyl-4-yl}-7-oxo -4,5,6,7-tetrahydro-1H-imidazolo[4,5-c]pyridine; 1-(3-aminobenzisoxazol-5'-yl)-6-{2'-[(methylamino)methyl]-1,1'-biphenyl-4-y l}-7-oxo-4,5,6,7-tetrahydro-1H-imidazolo[4,5-c]pyridine; 1-(3-aminobenzisoxazol-5'-yl)-6-{2'-[(dimethylamino)methyl]-1,1'-biphenyl-4 -yl}-7-oxo-4,5,6,7-tetrahydro-1H-imidazolo[4,5-c]pyridine; 1-(3-aminobenzisoxazol-5'-yl)-6-{2'-[(N-ethyl-N-methylamino)methyl]-1,1'-bi phenyl-4-yl}-7-oxo-4,5,6,7-tetrahydro-1H-imidazolo[4,5-c]pyridine; 1-(3-aminobenzisoxazol-5'-yl)-6-{2'-[(N-methyl-N-propylamino)methyl]-1,1'-b iphenyl-4-yl}-7-oxo-4,5,6,7-tetrahydro-1H-imidazolo[4,5-c]pyridine; 1-(3-aminobenzisoxazol-5'-yl)-6-{2'-[(N-t-butylamino)methyl]-1,1'-biphenyl- 4-yl}-7-oxo-4,5,6,7-tetrahydro-1H-imidazolo[4,5-c]pyridine; 6-(2'-{[1-pyrrolidinyl]methyl}-1,1'-biphenyl-4-yl)-1-(3-aminobenzisoxazol-5 '-yl)-7-oxo-4,5,6,7-tetrahydro-1H-imidazolo[4,5-c]pyridine; 6-(2'-{[(3S)-3-hydroxy-1-pyrrolidinyl]methyl}-1,1'-biphenyl-4-yl)-1-(3-amin obenzisoxazol-5'-yl)-7-oxo-4,5,6,7-tetrahydro-1H-imidazolo[4,5-c]pyridine; 6-(2-{[(3R)-3-hydroxy-1-pyrrolidinyl]methyl}-1,1'-biphenyl-4-yl)-1-(3-amino benzisoxazol-5'-yl)-7-oxo-4,5,6,7-tetrahydro-1H-imidazolo[4,5-c]pyridine; 6-{2'-[(4-hydroxy-1-piperidinyl)methyl]-1,1'-biphenyl-4-yl}-1-(3-aminobenzi soxazol-5'-yl)-7-oxo-4,5,6,7-tetrahydro-1H-imidazolo[4,5-c]pyridine; 6-{4-[3-(aminosulfonyl)-4-pyridinyl]phenyl}-1-(3-aminobenzisoxazol-5'-yl)-7 -oxo-4,5,6,7-tetrahydro-1H-imidazolo[4,5-c]pyridine; 6-(4-{2-[(dimethylamino)methyl]-1H-imidazol-1-yl}phenyl)-1-(3-aminobenzisox azol-5'-yl)-7-oxo-4,5,6,7-tetrahydro-1H-imidazolo[4,5-c]pyridine; 1-(3-aminobenzisoxazol-5'-yl)-6-[4-(2-methyl-1H-imidazol-1-yl)phenyl]-7-oxo -4,5,6,7-tetrahydro-1H-imidazolo[4,5-c]pyridine; 6-(2'-{[(2-hydroxyethyl)(methyl)amino]methyl}-1,1'-biphenyl-4-yl)-1-(3-amin obenzisoxazol-5'-yl)-7-oxo-4,5,6,7-tetrahydro-1H-imidazolo[4,5-c]pyridine; 6-(2'-{[(2-hydroxyethyl)amino]methyl}-1,1'-biphenyl-4-yl)-1-(3-aminobenziso xazol-5'-yl)-7-oxo-4,5,6,7-tetrahydro-1H-imidazolo[4,5-c]pyridine; 1-(3-aminobenzisoxazol-5'-yl)-6-(4-{2-[(methylamino)methyl]-1H-imidazol-1-y l}phenyl)-7-oxo-4,5,6,7-tetrahydro-1H-imidazolo[4,5-c]pyridine; 6-(2'-aminosulfonyl-1,1'-biphenyl-4-yl)-1-(3-aminobenzisoxazol-5'-yl)-7-oxo -4,5,6,7-tetrahydro-1H-imidazolo[4,5-c]pyridine; 6-(2'-methylsulfonyl-1,1'-biphenyl-4-yl)-1-(3-aminobenzisoxazol-5'-yl)-7-ox o-4,5,6,7-tetrahydro-1H-imidazolo[4,5-c]pyridine; 1-(3-aminobenzisoxazol-5'-yl)-6-{2'-[aminomethyl]-3-fluoro-1,1'-biphenyl-4- yl}-7-oxo-4,5,6,7-tetrahydro-1H-imidazolo[4,5-c]pyridine; 1-(3-aminobenzisoxazol-5'-yl)-6-{2'-[(methylamino)methyl]-3-fluoro-1,1'-bip henyl-4-yl}-7-oxo-4,5,6,7-tetrahydro-1H-imidazolo[4,5-c]pyridine; 1-(3-aminobenzisoxazol-5'-yl)-6-{2'-[(dimethylamino)methyl]-3-fluoro-1,1'-b iphenyl-4-yl}-7-oxo-4,5,6,7-tetrahydro-1H-imidazolo[4,5-c]pyridine; 1-(3-aminobenzisoxazol-5'-yl)-6-{2'-[(N-ethyl-N-methylamino)methyl]-3-fluor o-1,1'-biphenyl-4-yl}-7-oxo-4,5,6,7-tetrahydro-1H-imidazolo[4,5-c]pyridine; 1-(3-aminobenzisoxazol-5'-yl)-6-{2'-[(N-methyl-N-propylamino)methyl]-3-fluo ro-1,1'-biphenyl-4-yl}-7-oxo-4,5,6,7-tetrahydro-1H-imidazolo[4,5-c]pyridine ; 1-(3-aminobenzisoxazol-5'-yl)-6-{2'-[(N-t-butylamino)methyl]-3-fluoro-1,1'- biphenyl-4-yl}-7-oxo-4,5,6,7-tetrahydro-1H-imidazolo[4,5-c]pyridine; 6-(2'-{[1-pyrrolidinyl]methyl}-3-fluoro-1,1'-biphenyl-4-yl)-1-(3-aminobenzi soxazol-5'-yl)-7-oxo-4,5,6,7-tetrahydro-1H-imidazolo[4,5-c]pyridine; 6-(2'-{[(3S)-3-hydroxy-1-pyrrolidinyl]methyl}-3-fluoro-1,1'-biphenyl-4-yl)- 1-(3-aminobenzisoxazol-5'-yl)-7-oxo-4,5,6,7-tetrahydro-1H-imidazolo[4,5-c]p yridine; 6-(2'-{[(3R)-3-hydroxy-1-pyrrolidinyl]methyl}-3-fluoro-1,1'-biphenyl-4-yl)- 1-(3-aminobenzisoxazol-5'-yl)-7-oxo-4,5,6,7-tetrahydro-1H-imidazolo[4,5-c]p yridine; 6-{2'-[(4-hydroxy-1-piperidinyl)methyl]-3-fluoro-1,1'-biphenyl-4-yl}-1-(3-a minobenzisoxazol-5'-yl)-7-oxo-4,5,6,7-tetrahydro-1H-imidazolo[4,5-c]pyridin e; 6-{4-[3-(aminosulfonyl)-4-pyridinyl]-2-fluoro-phenyl}-1-(3-aminobenzisoxazo l-5'-yl)-7-oxo-4,5,6,7-tetrahydro-1H-imidazolo[4,5-c]pyridine; 6-(4-{2-[(dimethylamino)methyl]-1H-imidazol-1-yl}-2-fluoro-phenyl)-1-(3-ami nobenzisoxazol-5'-yl)-7-oxo-4,5,6,7-tetrahydro-1H-imidazolo[4,5-c]pyridine; 1-(3-aminobenzisoxazol-5'-yl)-6-[4-(2-methyl-1H-imidazol-1-yl)-2-fluoro-phe nyl]-7-oxo-4,5,6,7-tetrahydro-1H-imidazolo[4,5-c]pyridine; 6-(2'-{[(2-hydroxyethyl)(methyl)amino]methyl}-3-fluoro-1,1'-biphenyl-4-yl)- 1-(3-aminobenzisoxazol-5'-yl)-7-oxo-4,5,6,7-tetrahydro-1H-imidazolo[4,5-c]p yridine; 6-(2'-{[(2-hydroxyethyl)amino]methyl}-3-fluoro-1,1'-biphenyl-4-yl)-1-(3-ami nobenzisoxazol-5'-yl)-7-oxo-4,5,6,7-tetrahydro-1H-imidazolo[4,5-c]pyridine; 1-(3-aminobenzisoxazol-5'-yl)-6-(4-{2-[(methylamino)methyl]-1H-imidazol-1-y l}-2-fluoro-phenyl)-7-oxo-4,5,6,7-tetrahydro-1H-imidazolo[4,5-c]pyridine; 6-(2'-aminosulfonyl-3-fluoro-1,1'-biphenyl-4-yl)-1-(3-aminobenzisoxazol-5'- yl)-7-oxo-4,5,6,7-tetrahydro-1H-imidazolo[4,5-c]pyridine; 6-(2'-methylsulfonyl-3-fluoro-1,1'-biphenyl-4-yl)-1-(3-aminobenzisoxazol-5' -yl)-7-oxo-4,5,6,7-tetrahydro-1H-imidazolo[4,5-c]pyridine; 3-[4,5,6,7-tetrahydro-6-[2'-[aminomethyl][1,1'-biphenyl]-4-yl]-7-oxo-1H-imi dazolo[4,5-c]pyridin-1-yl]benzamide; 3-[4,5,6,7-tetrahydro-6-[2'-[[methylamino]methyl][1,1'-biphenyl]-4-yl]-7-ox o-1H-imidazolo[4,5-c]pyridin-1-yl]benzamide; 3-[4,5,6,7-tetrahydro-6-[2'-[[dimethylamino]methyl][1,1'-biphenyl]-4-yl]-7- oxo-1H-imidazolo[4,5-c]pyridin-1-yl]benzamide; 3-[4,5,6,7-tetrahydro-6-[2'-[[4-hydroxypiperidin-1-yl]methyl][1,1'-biphenyl ]-4-yl]-7-oxo-1H-imidazolo[4,5-c]pyridin-1-yl]benzamide; 3-[4,5,6,7-tetrahydro-6-[2'-[[N-ethyl-N-methylamino]methyl][1,1'-biphenyl]- 4-yl]-7-oxo-1H-imidazolo[4,5-c]pyridin-1-yl]benzamide; 3-[4,5,6,7-tetrahydro-6-[2'-[[pyrrolidin-1-yl]methyl][1,1'-biphenyl]-4-yl]- 7-oxo-1H-imidazolo[4,5-c]pyridin-1-yl]benzamide; 3-[4. 5,6,7-tetrahydro-6-[2'-[[3(R)-hydroxypyrrolidin-1-yl]methyl][1,1'-biphenyl ]-4-yl]-7-oxo-1H-imidazolo[4,5-c]pyridin-1-yl]benzamide; 3-[4,5,6,7-tetrahydro-6-[2'-[[3(S)-hydroxypyrrolidin-1-yl]methyl][1,1'-biph enyl]-4-yl]-7-oxo-1H-imidazolo[4,5-c]pyridin-1-yl]benzamide; 3-[4,5,6,7-tetrahydro-6-[2'-[[N-propyl-N-methylamino]methyl][1,1'-biphenyl] -4-yl]-7-oxo-1H-imidazolo[4,5-c]pyridin-1-yl]benzamide; 3-[4,5,6,7-tetrahydro-6-[2'-[[t-butylamino]methyl][1,1'-biphenyl]-4-yl]-7-o xo-1H-imidazolo[4,5-c]pyridin-1-yl]benzamide; 3-[4,5,6,7-tetrahydro-6-{4-[3-(aminosulfonyl)-4-pyridinyl]phenyl}-7-oxo-1H- imidazolo[4,5-c]pyridin-1-yl]benzamide; 3-[4,5,6,7-tetrahydro-6-(4-{2-[(dimethylamino)methyl]-1H-imidazol-1-yl}phen yl)-7-oxo-1H-imidazolo[4,5-c]pyridin-1-yl]benzamide; 3-[4,5,6,7-tetrahydro-6-[4-(2-methyl-1H-imidazol-1-yl)phenyl]-7-oxo-1H-imid

azolo[4,5-c]pyridin-1-yl]benzamide; 3-[4,5,6,7-tetrahydro-6-(2'-{[(2-hydroxyethyl)(methyl)amino]methyl}-1,1'-bi phenyl-4-yl)-7-oxo-1H-imidazolo[4,5-c]pyridin-1-yl]benzamide; 3-[4,5,6,7-tetrahydro-6-(2'-{[(2-hydroxyethyl)amino]methyl}-1,1'-biphenyl-4 -yl)-7-oxo-1H-imidazolo[4,5-c]pyridin-1-yl]benzamide; 3-[4,5,6,7-tetrahydro-6-(4-{2-[(methylamino)methyl]-1H-imidazol-1-yl}phenyl )-7-oxo-1H-imidazolo[4,5-c]pyridin-1-yl]benzamide; 3-[4,5,6,7-tetrahydro-6-(2'-aminosulfonyl-1,1'-biphenyl-4-yl)-7-oxo-1H-imid azolo[4,5-c]pyridin-1-yl]benzamide; 3-[4,5,6,7-tetrahydro-6-(2'-methylsulfonyl-1,1'-biphenyl-4-yl)-7-oxo-1H-imi dazolo[4,5-c]pyridin-1-yl]benzamide; 3-[4,5,6,7-tetrahydro-6-[2'-[aminomethyl]-3-fluoro-[1,1'-biphenyl]-4-yl]-7- oxo-1H-imidazolo[4,5-c]pyridin-1-yl]benzamide; 3-[4,5,6,7-tetrahydro-6-[2'-[[methylamino]methyl]-3-fluoro-[1,1'-biphenyl]- 4-yl]-7-oxo-1H-imidazolo[4,5-c]pyridin-1-yl]benzamide; 3-[4,5,6,7-tetrahydro-6-[2'-[[dimethylamino]methyl]-3-fluoro-[1,1'-biphenyl ]-4-yl]-7-oxo-1H-imidazolo[4,5-c]pyridin-1-yl]benzamide; 3-[4,5,6,7-tetrahydro-6-[2'-[[4-hydroxypiperidin-1-yl]methyl]-3-fluoro-[1,1 '-biphenyl]-4-yl]-7-oxo-1H-imidazolo[4,5-c]pyridin-1-yl]benzamide; 3-[4,5,6,7-tetrahydro-6-[2'-[[N-ethyl-N-methylamino]methyl]-3-fluoro-[1,1'- biphenyl]-4-yl]-7-oxo-1H-imidazolo[4,5-c]pyridin-1-yl]benzamide; 3-[4,5,6,7-tetrahydro-6-[2'-[[pyrrolidin-1-yl]methyl]-3-fluoro-[1,1'-biphen yl]-4-yl]-7-oxo-1H-imidazolo[4,5-c]pyridin-1-yl]benzamide; 3-[4,5,6,7-tetrahydro-6-[2'-[[3(R)-hydroxypyrrolidin-1-yl]methyl]-3-fluoro- [1,1'-biphenyl]-4-yl]-7-oxo-1H-imidazolo[4,5-c]pyridin-1-yl]benzamide; 3-[4,5,6,7-tetrahydro-6-[2'-[[3(S)-hydroxypyrrolidin-1-yl]methyl]-3-fluoro- [1,1'-biphenyl]-4-yl]-7-oxo-1H-imidazolo[4,5-c]pyridin-1-yl]benzamide; 3-[4,5,6,7-tetrahydro-6-[2'-[[N-propyl-N-methylamino]methyl]-3-fluoro-[1,1' -biphenyl]-4-yl]-7-oxo-1H-imidazolo[4,5-c]pyridin-1-yl]benzamide; 3-[4,5,6,7-tetrahydro-6-[2'-[[t-butylamino]methyl]-3-fluoro-[1,1'-biphenyl] -4-yl]-7-oxo-1H-imidazolo[4,5-c]pyridin-1-yl]benzamide; 3-[4,5,6,7-tetrahydro-6-{4-[3-(aminosulfonyl)-4-pyridinyl]-2-fluoro-phenyl} -7-oxo-1H-imidazolo[4,5-c]pyridin-1-yl]benzamide; 3-[4,5,6,7-tetrahydro-6-(4-{2-[(dimethylamino)methyl]-1H-imidazol-1-yl}-2-f luoro-phenyl)-7-oxo-1H-imidazolo[4,5-c]pyridin-1-yl]benzamide; 3-[4,5,6,7-tetrahydro-6-[4-(2-methyl-1H-imidazol-1-yl)-2-fluoro-phenyl]-7-o xo-1H-imidazolo[4,5-c]pyridin-1-yl]benzamide; 3-[4,5,6,7-tetrahydro-6-(2'-{[(2-hydroxyethyl)(methyl)amino]methyl}-3-fluor o-1,1'-biphenyl-4-yl)-7-oxo-1H-imidazolo[4,5-c]pyridin-1-yl]benzamide; 3-[4,5,6,7-tetrahydro-6-(2'{[(2-hydroxyethyl)amino]methyl}-3-fluoro-1,1'-bi phenyl-4-yl)-7-oxo-1H-imidazolo[4,5-c]pyridin-1-yl]benzamide; 3-[4,5,6,7-tetrahydro-6-(4-{2-[(methylamino)methyl]-1H-imidazol-1-yl}-2-flu oro-phenyl)-7-oxo-1H-imidazolo[4,5-c]pyridin-1-yl]benzamide; 3-[4,5,6,7-tetrahydro-6-(2'-aminosulfonyl-3-fluoro-1,1'-biphenyl-4-yl)-7-ox o-1H-imidazolo[4,5-c]pyridin-1-yl]benzamide; and, 3-[4,5,6,7-tetrahydro-6-(2'-methylsulfonyl-3-fluoro-1,1'-biphenyl-4-yl)-7-o xo 1H-imidazolo[4,5-c]pyridin-1-yl]benzamide; or a pharmaceutically acceptable salt form thereof.

8. A pharmaceutical composition, comprising: a pharmaceutically acceptable carrier and a therapeutically effective amount of a compound according to claim 1 or a pharmaceutically acceptable salt thereof.

9. A method for treating a thromboembolic disorder, comprising: administering to a patient in need thereof a therapeutically effective amount of a compound according to claim 1 or a pharmaceutically acceptable salt thereof.

10. A pharmaceutical composition, comprising: a pharmaceutically acceptable carrier and a therapeutically effective amount of a compound according to claim 2 or a pharmaceutically acceptable salt thereof.

11. A method for treating a thromboembolic disorder, comprising: administering to a patient in need thereof a therapeutically effective amount of a compound according to claim 2 or a pharmaceutically acceptable salt thereof.

12. A pharmaceutical composition, comprising: a pharmaceutically acceptable carrier and a therapeutically effective amount of a compound according to claim 3 or a pharmaceutically acceptable salt thereof.

13. A method for treating a thromboembolic disorder, comprising: administering to a patient in need thereof a therapeutically effective amount of a compound according to claim 3 or a pharmaceutically acceptable salt thereof.

14. A pharmaceutical composition, comprising: a pharmaceutically acceptable carrier and a therapeutically effective amount of a compound according to claim 4 or a pharmaceutically acceptable salt thereof.

15. A method for treating a thromboembolic disorder, comprising: administering to a patient in need thereof a therapeutically effective amount of a compound according to claim 4 or a pharmaceutically acceptable salt thereof.

16. A pharmaceutical composition, comprising: a pharmaceutically acceptable carrier and a therapeutically effective amount of a compound according to claim 5 or a pharmaceutically acceptable salt thereof.

17. A method for treating a thromboembolic disorder, comprising: administering to a patient in need thereof a therapeutically effective amount of a compound according to claim 5 or a pharmaceutically acceptable salt thereof.

18. A pharmaceutical composition, comprising: a pharmaceutically acceptable carrier and a therapeutically effective amount of a compound according to claim 6 or a pharmaceutically acceptable salt thereof.

19. A method for treating a thromboembolic disorder, comprising: administering to a patient in need thereof a therapeutically effective amount of a compound according to claim 6 or a pharmaceutically acceptable salt thereof.

20. A pharmaceutical composition, comprising: a pharmaceutically acceptable carrier and a therapeutically effective amount of a compound according to claim 7 or a pharmaceutically acceptable salt thereof.

21. A method for treating a thromboembolic disorder, comprising: administering to a patient in need thereof a therapeutically effective amount of a compound according to claim 7 or a pharmaceutically acceptable salt thereof.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc